Nakazawa M, Emancipator S N, Lamm M E
J Exp Med. 1986 Dec 1;164(6):1973-87. doi: 10.1084/jem.164.6.1973.
We investigated the effect of proteolytic enzyme treatment on the course of passive Heymann nephritis (PHN). PHN was induced by intravenous injection of Heymann antibody into Sprague Dawley rats. Protease-treated rats received intraperitoneal chymopapain and subtilisin. In rats given subnephritogenic doses of Heymann antibody (5 or 10 mg, insufficient to cause proteinuria), glomerular immune deposits were assessed by immunofluorescence and electron microscopy. In rats given 5 mg Heymann antibody and treated with protease in the heterologous phase of the disease (days 1-7), fewer animals were positive for rabbit IgG and rat IgG, as determined by immunofluorescence on day 12, compared with controls (p less than 0.01). Rats given 10 mg Heymann antibody and treated on days 1-5 were less frequently positive for rabbit IgG on day 5 than controls (p less than 0.05). When treatment was given on days 6-12 (autologous phase), fewer rats had glomerular rabbit and rat IgG compared with controls (p less than 0.025). Protease treatment of rats given nephritogenic doses of Heymann antibody (greater than or equal to 40 mg, causing proteinuria) did not result in significant differences in immunofluorescence deposits. However, protease treatment significantly reduced the number of electron dense deposits at all doses of antibody (p less than 0.01). Furthermore, rats given 60 mg Heymann antibody followed by enzyme treatment in the heterologous phase (days 1-7) or throughout the autologous phase (days 6-18) had significantly reduced protein excretion during the autologous phase compared with control rats (p less than 0.05). After onset of significant proteinuria on day 15 in rats given 40 mg Heymann antibody and treated from day 15 until day 25, there was significantly less (p less than 0.05) proteinuria on days 21-22 and 24-25 than in control rats; thus, enzymes could reverse proteinuria. In normal rats, administration of proteases did not have significant effects on urinary protein excretion, serum creatinine, or renal morphology, nor did protease affect anti-rabbit IgG antibody production in rats injected with Heymann antibody. The overall results indicate that proteolytic enzyme treatment can prevent or remove glomerular immune deposits and can prevent or reverse proteinuria.
我们研究了蛋白水解酶处理对被动型海曼肾炎(PHN)病程的影响。通过向Sprague Dawley大鼠静脉注射海曼抗体诱导产生PHN。蛋白酶处理的大鼠接受腹腔注射木瓜凝乳蛋白酶和枯草杆菌蛋白酶。对于给予亚肾炎剂量海曼抗体(5或10毫克,不足以引起蛋白尿)的大鼠,通过免疫荧光和电子显微镜评估肾小球免疫沉积物。对于给予5毫克海曼抗体并在疾病的异源期(第1 - 7天)用蛋白酶处理的大鼠,与对照组相比,在第12天通过免疫荧光测定,阳性表达兔IgG和大鼠IgG的动物较少(p小于0.01)。给予10毫克海曼抗体并在第1 - 5天进行处理的大鼠,在第5天兔IgG阳性的频率低于对照组(p小于0.05)。当在第6 - 12天(自体期)进行处理时,与对照组相比,有较少的大鼠肾小球存在兔和大鼠IgG(p小于0.025)。对给予肾炎剂量海曼抗体(大于或等于40毫克,引起蛋白尿)的大鼠进行蛋白酶处理,在免疫荧光沉积物方面未产生显著差异。然而,蛋白酶处理在所有抗体剂量下均显著减少了电子致密沉积物的数量(p小于0.01)。此外,给予60毫克海曼抗体并在异源期(第1 - 7天)或整个自体期(第6 - 18天)进行酶处理的大鼠,与对照大鼠相比,在自体期的蛋白尿排泄显著减少(p小于0.05)。在给予40毫克海曼抗体并从第15天至第25天进行处理的大鼠中,在第15天出现显著蛋白尿后,在第21 - 22天和24 - 25天的蛋白尿明显少于对照大鼠(p小于0.05);因此,酶可以逆转蛋白尿。在正常大鼠中,给予蛋白酶对尿蛋白排泄、血清肌酐或肾脏形态没有显著影响,蛋白酶也不影响注射海曼抗体的大鼠中抗兔IgG抗体的产生。总体结果表明,蛋白水解酶处理可以预防或清除肾小球免疫沉积物,并可以预防或逆转蛋白尿。